Please provide your email address to receive an email when new articles are posted on . Radionuclide bone scans may not correlate with other radiographic and clinical findings and are not warranted ...

In the study, mice bearing prostate cancer tumors received one of four treatments: an isotope control antibody, 225Ac-PSMA617 radionuclide therapy, an anti-PD-1 antibody or both 225Ac-PSMA617 ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new ...

Nuclear medicine therapy uses radiopharmaceuticals targeting specific tumours, such as thyroid, lymphomas or bone metastases, delivering radiation to tumorous lesions as part of a therapeutic strategy ...

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. Nuclear medicine plays a very important role in the ...

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is ...

γ-emitting isotopes are selected for diagnosis because the radiation they produce can be detected by specific instruments such as positron emission tomography (PET) or single-photon emission computed ...

Radionuclide therapy delivered directly to an artery is safe and feasible for patients with advanced meningioma, according to new research published in the December issue of The Journal of Nuclear ...